Karadurmus Nuri, Sahin Ugur, Bahadir Basgoz Bilgin, Arpaci Fikret, Demirer Taner
Gulhane Military Medical Academy, Department of Medical Oncology, Etlik, Ankara, Turkey.
Ankara University Medical School, Department of Hematology, Ankara, Turkey.
Int J Hematol Oncol Stem Cell Res. 2018 Apr 1;12(2):111-116.
Breast cancer (BC) has a high mortality rate and metastatic BC is almost incurable despite hormonal therapy and chemotherapy. The second and third lines of chemotherapies usually yield transient responses and the median survival is generally as low as 18-24 months. Autologous and allogeneic hematopoietic stem cell transplantation (HSCT) have been extensively investigated in this setting. The presence of immune mediated anti-tumor effects referred to as graft-versus-tumor (GvT) effects after allogeneic HSCT among patients with solid tumors have been clearly defined. The advantages of allogeneic HSCT over autologous HSCT for metastatic BC are i) cancer-free graft and ii) immune-mediated GvT effects mediated by human leukocyte antigen compatible donor T-cells. In conclusion, a GvT effect does exist against metastatic BC and play a key role in tumor response. This review aims to describe the background, rationale, and clinical results of allogeneic HSCT as a potential alternative treatment in metastatic BC.
乳腺癌（BC）死亡率很高，尽管有激素疗法和化疗，转移性乳腺癌几乎无法治愈。二线和三线化疗通常只能产生短暂的反应，中位生存期通常低至18 - 24个月。自体和异基因造血干细胞移植（HSCT）已在这种情况下进行了广泛研究。实体瘤患者接受异基因HSCT后存在免疫介导的抗肿瘤效应，即移植物抗肿瘤（GvT）效应，这一点已得到明确界定。异基因HSCT相对于自体HSCT治疗转移性乳腺癌的优势在于：i）无癌移植物；ii）由人类白细胞抗原相容供体T细胞介导的免疫介导的GvT效应。总之，针对转移性乳腺癌确实存在GvT效应，且在肿瘤反应中起关键作用。本综述旨在描述异基因HSCT作为转移性乳腺癌潜在替代治疗方法的背景、原理和临床结果。
